IRONWOOD PHARMACEUTICALS INC - 8-K Filing

Ironwood Pharmaceuticals raises full-year 2026 revenue and EBITDA guidance following strong Q3 results and LINZESS sales growth. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $IRWD

Read the full article at SEC EDGAR

More Regulatory news